Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2020 08:30 ET | Source: Monopar Therapeutics Inc.

Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM WILMETTE, Ill., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a...